DSMB and Spectral's ability to determine "sample size"This trial had a VERY wide range in the area of "composite mortality"
From an initial 40% reported to a low of 30% and a high of 55% as reported by Cormark.
It would seem to me that Spectral and other PMX experts have a good idea of "where this works"
Take for example the area of "abdominal sepsis" which is a focus for the product in Asia anf Japan.
Was the 18% absolute benfit reported on this particular group ( about 40% of all severe septic cases )?
If so, why weren't we told a little more about the 18% and why didn't the young lady from Reuters mention it in here global blast?
It was very couteous of Cormark and Mackie to issue updates immediately after the news at prices of 4 and 5 cents respectively...they were quite "quick" to weigh in.
The activity around this company has become questionable and the fact NOBODY on the inside has sold and Americans are NOW BUYING is a source of interest.